These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33933238)

  • 1. 10 Years of End-of-Life Criteria in the United Kingdom.
    Bovenberg J; Penton H; Buyukkaramikli N
    Value Health; 2021 May; 24(5):691-698. PubMed ID: 33933238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access.
    Njoroge MW; Walton M; Hodgson R
    Value Health; 2024 Jun; 27(6):730-736. PubMed ID: 38447743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
    de Folter J; Trusheim M; Jonsson P; Garner S
    Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses.
    Stevenson MD; Scope A; Sutcliffe PA; Booth A; Slade P; Parry G; Saxon D; Kalthenthaler E;
    Health Technol Assess; 2010 Sep; 14(44):1-107, iii-iv. PubMed ID: 20863477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NICE cost-effectiveness threshold: what it is and what that means.
    McCabe C; Claxton K; Culyer AJ
    Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints.
    McHugh N; van Exel J; Mason H; Godwin J; Collins M; Donaldson C; Baker R
    Soc Sci Med; 2018 Feb; 198():61-69. PubMed ID: 29276987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence and values: paying for end-of-life drugs in the British NHS.
    Chalkidou K
    Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity-Adjusted Probability of Being Cost Effective.
    Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
    Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
    Pennington BM
    Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
    Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
    Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
    Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
    Devlin N; Parkin D
    Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.